218 related articles for article (PubMed ID: 30526633)
1. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Brooks JD; Comen EA; Reiner AS; Orlow I; Leong SF; Liang X; Mellemkjær L; Knight JA; Lynch CF; John EM; Bernstein L; Woods M; Doody DR; ; Malone KE; Bernstein JL
Breast Cancer Res; 2018 Dec; 20(1):149. PubMed ID: 30526633
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Goetz MP; Suman VJ; Hoskin TL; Gnant M; Filipits M; Safgren SL; Kuffel M; Jakesz R; Rudas M; Greil R; Dietze O; Lang A; Offner F; Reynolds CA; Weinshilboum RM; Ames MM; Ingle JN
Clin Cancer Res; 2013 Jan; 19(2):500-7. PubMed ID: 23213055
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
6. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
9. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
11. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.
Park HS; Choi JY; Lee MJ; Park S; Yeo CW; Lee SS; Shin JG; Park BW
J Korean Med Sci; 2011 Aug; 26(8):1007-13. PubMed ID: 21860550
[TBL] [Abstract][Full Text] [Related]
12. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
15. Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Brewer NT; Defrank JT; Chiu WK; Ibrahim JG; Walko CM; Rubin P; Olajide OA; Moore SG; Raab RE; Carrizosa DR; Corso SW; Schwartz G; Peppercorn JM; McLeod HL; Carey LA; Irvin WJ
Public Health Genomics; 2014; 17(1):43-7. PubMed ID: 24457521
[TBL] [Abstract][Full Text] [Related]
16. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
Li J; Czene K; Brauch H; Schroth W; Saladores P; Li Y; Humphreys K; Hall P
Breast Cancer Res; 2013; 15(5):R93. PubMed ID: 24088226
[TBL] [Abstract][Full Text] [Related]
18. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Irvin WJ; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA
J Clin Oncol; 2011 Aug; 29(24):3232-9. PubMed ID: 21768473
[TBL] [Abstract][Full Text] [Related]
19. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
Langballe R; Mellemkjær L; Malone KE; Lynch CF; John EM; Knight JA; Bernstein L; Brooks J; Andersson M; Reiner AS; Liang X; Woods M; Concannon PJ; ; Bernstein JL
Breast Cancer Res; 2016 Jul; 18(1):65. PubMed ID: 27400983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
